ARTICLES BY MARJORIE ZETTLER

  • FDA headquarter iStock-1213293784
    FDA's RTOR Program: Draft Guidance & Insights
    10/4/2022

    First launched in Feb. 2018 by the FDA’s Oncology Center of Excellence, the Real-Time Oncology Review (RTOR) program is intended to streamline the review process for oncology drug applications. This article summarizes the new guidance and reviews the performance of the program thus far.

Marjorie

Marjorie Zettler

Marjorie Zettler, Ph.D., MPH is a consultant, clinical sciences with the Conjugate Group and a 2022 Woman Worth Watching in STEM. An award-winning industry veteran with two decades' experience in clinical research, drug development, and regulatory strategy, she has published over 100 abstracts, manuscripts, book chapters, and patents.